Application of MRPL41 gene / protein in the preparation of drugs for treating age-related sarcopenia

CN122351433APending Publication Date: 2026-07-10SUN YAT SEN UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610845960.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-06-12
Publication Date
2026-07-10

AI Technical Summary

Technical Problem

Existing treatments for age-related sarcopenia suffer from poor adherence, difficulty in overcoming anabolism resistance, and systemic side effects. They also lack precise intervention strategies targeting the mitochondrial translational machinery and cannot effectively restore muscle regeneration potential.

Method used

By injecting the AAV9-MRPL41 vector, which promotes the expression of the MRPL41 gene/protein, the assembly disorder of the 55S holoenzyme of mitochondria is repaired, myosatellite cell regeneration is promoted, and mitochondrial dysfunction is improved.

Benefits of technology

It significantly restores muscle mass and metabolic function, improves mitochondrial function in aging muscle satellite cells, overcomes anabolism resistance, and provides a specific microscopic target for reversing mitochondrial translation defects, breaking through the limitations of existing therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122351433A_ABST
    Figure CN122351433A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biomedical technology, specifically involving the application of the MRPL41 gene / protein in the preparation of drugs for treating age-related sarcopenia. This invention is the first to demonstrate that MRPL41 is a key rate-limiting factor in the assembly of mitochondrial ribosomes in aging muscle satellite cells, establishing it as a core target for the treatment of age-related sarcopenia. Overexpression of MRPL41 can promote the assembly of mitochondrial 55S holoenzymes, improve the translation efficiency of mitochondrial-encoded proteins, repair mitochondrial dysfunction at its source, thereby promoting muscle repair, improving muscle atrophy, and achieving the treatment of age-related sarcopenia. This invention provides a precise microscopic target for the treatment of age-related sarcopenia, overcoming the limitations of existing clinical therapies (such as hormone replacement and simple nutritional supplementation) due to significant side effects and "anabolism resistance," providing a new direction for the development of innovative drugs specifically for the treatment of age-related sarcopenia, and has excellent application prospects.
Need to check novelty before this filing date? Find Prior Art